SCHEMBL16634764

SCHEMBL16634764

O=C(CO)[C@@H](OP(=O)(O)O)[C@H](O)[C@H](O)[C@H](O)CO

nearest known ligand 0.39

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PDE4A P27815 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
USP2 O75604 1/20 0.36
SLCO1B1 Q9Y6L6 1/20 0.36
PGD P52209 2/20 0.31
KDM4E B2RXH2 2/20 0.31
CYP2C9 P11712 1/20 0.31
TSHR P16473 1/20 0.31
PTPN1 P18031 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19514767 0.95 LMNA (0.36) LMNAL3MBTL1PDE4ATDP1USP2
SCHEMBL896315 0.95 LMNA (0.36) LMNAL3MBTL1PDE4ATDP1USP2
SCHEMBL28352023 0.95 LMNA (0.36) LMNAL3MBTL1PDE4ATDP1USP2
SCHEMBL16038475 0.87 PGD (0.33) PGDPTPN1
SCHEMBL20603238 0.87 PGD (0.33) PGDPTPN1
SCHEMBL7076428 0.86 PDE4A (0.32) LMNAL3MBTL1PDE4ATDP1USP2
SCHEMBL2422500 0.84 PDE4A (0.48) LMNAL3MBTL1PDE4ATDP1USP2
SCHEMBL1527670 0.81 PDE4A (0.46) LMNAL3MBTL1PDE4ATDP1USP2
SCHEMBL27661966 0.80 USP2 (0.33) LMNAL3MBTL1PDE4ATDP1USP2
SCHEMBL4959396 0.79 PGD (0.36) LMNAL3MBTL1PDE4APGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118360173-A Method for synthesizing erythrose 4-phosphate precursor and erythritol 中国科学院微生物研究所 2024-07-19 CN claimed
US-20250305014-A1 CORYNEBACTERIUM GLUTAMICUM VARIANT WITH IMPROVED L-LYSINE PRODUCTION ABILITY, AND METHOD FOR PRODUCING L-LYSINE USING SAME CJ CHEILJEDANG CORPORATION (KR) 2025-10-02 US disclosed
CN-115261294-B Corynebacterium glutamicum mutant strain having improved L-lysine productivity and method for producing L-lysine using same 大象株式会社 2024-03-29 CN disclosed
EP-4332230-A1 CORYNEBACTERIUM GLUTAMICUM VARIANT WITH IMPROVED L-LYSINE PRODUCTION ABILITY, AND METHOD FOR PRODUCING L-LYSINE USING SAME CJ Cheiljedang Corporation (KR) 2024-03-06 EP disclosed
CN-117511834-A Corynebacterium glutamicum mutant strain having improved L-lysine productivity and method for producing L-lysine using same CJ第一制糖株式会社 2024-02-06 CN disclosed
US-11634701-B2 Metabolic pathways with increased carbon yield TOTAL RAFFINAGE CHIMIE (FR) 2023-04-25 US disclosed
WO-2022231056-A1 CORYNEBACTERIUM GLUTAMICUM VARIANT WITH IMPROVED L-LYSINE PRODUCTION ABILITY, AND METHOD FOR PRODUCING L-LYSINE USING SAME 대상 주식회사 2022-11-03 WO disclosed
CN-115261294-A Corynebacterium glutamicum mutant strain having improved L-lysine productivity and method for producing L-lysine using the same 大象株式会社 2022-11-01 CN disclosed
CN-106165175-B High molecular electrolyte composition and polyelectrolyte membrane, film electrode composite element and the polymer electrolyte fuel cell for using it 东丽株式会社 2019-11-08 CN disclosed
US-10103401-B2 Polymer electrolyte composition and polymer electrolyte membrane, polymer electrolyte membrane with catalyst layer, membrane electrode assembly, and polymer electrolyte fuel cell each using the same TORAY INDUSTRIES, INC. (JP) 2018-10-16 US disclosed
EP-3131145-B1 POLYMER ELECTROLYTE COMPOSITION AND POLYMER ELECTROLYTE MEMBRANE, MEMBRANE-ELECTROLYTE ASSEMBLY, AND SOLID POLYMER FUEL CELL USING SAME TORAY INDUSTRIES (JP) 2018-09-05 EP disclosed
US-20170125832-A1 POLYMER ELECTROLYTE COMPOSITION AND POLYMER ELECTROLYTE MEMBRANE, POLYMER ELECTROLYTE MEMBRANE WITH CATALYST LAYER, MEMBRANE ELECTRODE ASSEMBLY, AND POLYMER ELECTROLYTE FUEL CELL EACH USING THE SAME TORAY INDUSTRIES, INC. (JP) 2017-05-04 US disclosed
EP-3131145-A1 POLYMER ELECTROLYTE COMPOSITION AND POLYMER ELECTROLYTE MEMBRANE, MEMBRANE-ELECTROLYTE ASSEMBLY, AND SOLID POLYMER FUEL CELL USING SAME Toray Industries, Inc. (JP) 2017-02-15 EP disclosed
EP-3055304-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS Eli Lilly and Company (US) 2016-08-17 EP disclosed
US-20160229835-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS ELI LILLY AND COMPANY 2016-08-11 US disclosed
WO-2015054060-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS ELI LILLY AND COMPANY (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160229835-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS NAMPT, NAPRT, NNMT LMNA 1449/4885L3MBTL1 2527/4885PDE4A 1214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.